{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T10:54:38Z","timestamp":1783421678270,"version":"3.54.6"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1097\/mnm.0000000000000477","type":"journal-article","created":{"date-parts":[[2016,1,7]],"date-time":"2016-01-07T12:30:47Z","timestamp":1452169847000},"page":"453-460","source":"Crossref","is-referenced-by-count":36,"title":["Diagnostic performance of 18F-FDG PET\/contrast-enhanced CT versus contrast-enhanced CT alone for post-treatment detection of ovarian malignancy"],"prefix":"10.1097","volume":"37","author":[{"given":"Ahmed","family":"Tawakol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasser G.","family":"Abdelhafez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Osama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherif","family":"El Refaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210212","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1525-1438.2007.00826.x","article-title":"Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature.","volume":"17","author":"Gadducci","year":"2007","journal-title":"Int J Gynecol Cancer"},{"key":"R2-3-20210212","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S1470-2045(07)70273-5","article-title":"Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations.","volume":"8","author":"Goonewardene","year":"2007","journal-title":"Lancet Oncol"},{"key":"R3-3-20210212","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1007\/s00330-010-1886-4","article-title":"ESUR guidelines: ovarian cancer staging and follow-up.","volume":"20","author":"Forstner","year":"2010","journal-title":"Eur Radiol"},{"key":"R5-3-20210212","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejrad.2010.11.039","article-title":"Ovarian cancer management: the role of imaging and diagnostic challenges.","volume":"78","author":"Bharwani","year":"2011","journal-title":"Eur J Radiol"},{"key":"R6-3-20210212","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2214\/ajr.176.6.1761449","article-title":". Clinical value of positron emission tomography with FDG for recurrent ovarian cancer.","volume":"176","author":"Nakamoto","year":"2001","journal-title":"Am J Roentgenol"},{"key":"R7-3-20210212","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1148\/radiol.2332031800","article-title":". Integrated FDG PETCT in patients with persistent ovarian cancer: correlation with histologic findings.","volume":"233","author":"Sironi","year":"2004","journal-title":"Radiology"},{"key":"R8-3-20210212","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1148\/rg.241035078","article-title":"PET-CT in recurrent ovarian cancer: initial observations.","volume":"24","author":"Pannu","year":"2004","journal-title":"Radiographics"},{"key":"R9-3-20210212","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ejrad.2005.04.006","article-title":". Evaluation of integrated whole-body PETCT in the detection of recurrent ovarian cancer.","volume":"56","author":"Hauth","year":"2005","journal-title":"Eur J Radiol"},{"key":"R10-3-20210212","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ygyno.2005.06.019","article-title":"Combined PETCT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes.","volume":"99","author":"Bristow","year":"2005","journal-title":"Gynecol Oncol"},{"key":"R11-3-20210212","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1007\/s00259-006-0306-0","article-title":". Integrated PETCT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer.","volume":"34","author":"Mangili","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R12-3-20210212","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ygyno.2006.10.060","article-title":"Clinical use of combined positron emission tomography and computed tomography (FDG-PETCT) in recurrent ovarian cancer.","volume":"105","author":"Thrall","year":"2007","journal-title":"Gynecol Oncol"},{"key":"R13-3-20210212","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s00259-006-0260-x","article-title":". Role of 18FFDG PETCT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings.","volume":"34","author":"Chung","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R14-3-20210212","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s00261-007-9218-0","article-title":". PET-CT vs. CT alone in ovarian cancer recurrence.","volume":"33","author":"Sebastian","year":"2008","journal-title":"Abdom Imaging"},{"key":"R15-3-20210212","first-page":"77","article-title":". Advanced ovarian carcinoma: usefulness of (18)FFDG-PET in combination with CT for lesion detection after primary treatment.","volume":"47","author":"Picchio","year":"2003","journal-title":"Q J Nucl Med"},{"key":"R16-3-20210212","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/MNM.0b013e32831089cb","article-title":"18F-FDG PETCT evaluation of patients with ovarian carcinoma.","volume":"29","author":"Iagaru","year":"2008","journal-title":"Nucl Med Commun"},{"key":"R17-3-20210212","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s00259-008-0776-3","article-title":". Performance of integrated FDG-PETcontrast-enhanced CT in the diagnosis of recurrent ovarian cancer: comparison with integrated FDG-PETnon-contrast-enhanced CT and enhanced CT.","volume":"35","author":"Kitajima","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R18-3-20210212","first-page":"1259","article-title":"Clinical value of FDG PETCT in the diagnosis of suspected recurrent ovarian cancer: is there an impact of FDG PETCT on patient management Eur J Nucl Med Mol I","volume":"37","author":"Bilici","year":"2010","journal-title":"maging"},{"key":"R19-3-20210212","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/IGC.0b013e3181e82a7f","article-title":". Clinical utility of positron emission tomographycomputed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels.","volume":"20","author":"Bhosale","year":"2010","journal-title":"Int J Gynecol Cancer"},{"key":"R20-3-20210212","first-page":"3","article-title":". The role of FDG-PETCT in ovarian cancer patients with high tumor markers or suspicious lesion on contrast-enhanced CT in evaluation of recurrence andor in determination of intra-abdominal metastases.","volume":"31","author":"Sari","year":"2012","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"key":"R21-3-20210212","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3892\/ol.2012.1075","article-title":"Staging recurrent ovarian cancer with (18)FDG PETCT.","volume":"5","author":"Dragosavac","year":"2013","journal-title":"Oncol Lett"},{"key":"R22-3-20210212","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.1097\/RLU.0b013e31825b2583","article-title":". Revisiting the clinical value of 18F-FDG PETCT in detection of recurrent epithelial ovarian carcinomas: correlation with histology, serum CA-125 assay, and conventional radiological modalities.","volume":"37","author":"Antunovic","year":"2012","journal-title":"Clin Nucl Med"},{"key":"R23-3-20210212","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00404-010-1404-6","article-title":"Combined positron emission tomography-computed tomography and tumor markers for detecting recurrent ovarian cancer.","volume":"283","author":"Pan","year":"2011","journal-title":"Arch Gynecol Obstet"},{"key":"R24-3-20210212","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1006\/gyno.2001.6246","article-title":"Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy.","volume":"82","author":"Rose","year":"2001","journal-title":"Gynecol Oncol"},{"key":"R25-3-20210212","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ejso.2005.02.029","article-title":". (18)F-FDG PETCT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients.","volume":"31","author":"Nanni","year":"2005","journal-title":"Eur J Surg Oncol"},{"key":"R26-3-20210212","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1016\/j.ejrad.2010.07.013","article-title":". FDG-PETCT in advanced ovarian cancer staging: value and pitfalls in detecting lesions in different abdominal and pelvic quadrants compared with laparoscopy.","volume":"80","author":"De Iaco","year":"2011","journal-title":"Eur J Radiol"},{"key":"R27-3-20210212","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1007\/s00259-007-0366-9","article-title":"Diagnostic accuracy of FDG PET in the follow-up of platinum-sensitive epithelial ovarian carcinoma.","volume":"34","author":"Garcia-Velloso","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R28-3-20210212","first-page":"1225","article-title":". Concurrent PETCT with an integrated imaging system: intersociety dialogue from the joint working group of the American College of Radiology, the Society of Nuclear Medicine, and the Society of Computed Body Tomography and Magnetic Resonance.","volume":"46","author":"Coleman","year":"2005","journal-title":"J Nucl Med"},{"key":"R29-3-20210212","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s12149-008-0227-z","article-title":"Benign ovarian and endometrial uptake on FDG PET-CT: patterns and pitfalls.","volume":"23","author":"Liu","year":"2009","journal-title":"Ann Nucl Med"},{"key":"R30-3-20210212","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/RLU.0b013e31826390ec","article-title":"Peritoneal carcinomatosis in patients with ovarian cancer: enhanced CT versus 18F-FDG PETCT.","volume":"38","author":"Kim","year":"2013","journal-title":"Clin Nucl Med"},{"key":"R31-3-20210212","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ejrad.2007.11.032","article-title":"Detection of histologically proven peritoneal carcinomatosis with fused 18F-FDG-PETMDCT.","volume":"69","author":"Dirisamer","year":"2009","journal-title":"Eur J Radiol"},{"key":"R32-3-20210212","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00261-009-9578-8","article-title":"Peritoneal carcinomatosis from ovarian cancer: the role of CT and (18)FFDG-PETCT.","volume":"35","author":"Funicelli","year":"2010","journal-title":"Abdom Imaging"},{"key":"R33-3-20210212","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1007\/s00259-008-0890-2","article-title":"Diagnostic accuracy of integrated FDG-PETcontrast-enhanced CT in staging ovarian cancer: comparison with enhanced CT.","volume":"35","author":"Kitajima","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R34-3-20210212","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.ejrad.2011.01.112","article-title":"Computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomographycomputer tomography for detection of metastatic lymph nodes in patients with ovarian cancer: a meta-analysis.","volume":"81","author":"Yuan","year":"2012","journal-title":"Eur J Radiol"},{"key":"R35-3-20210212","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/978-1-61779-062-1_10","article-title":"Gynecological cancers.","volume":"727","author":"Avril","year":"2011","journal-title":"Methods Mol Biol"},{"key":"R36-3-20210212","first-page":"54","article-title":"FDG PETCT in ovarian cancer: what about treatment response and prognosis Clin Nucl M","volume":"37","author":"Grassetto","year":"2012","journal-title":"ed"},{"key":"R37-3-20210212","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ygyno.2008.08.027","article-title":"The impact of PET-CT in suspected recurrent ovarian cancer: a prospective multi-centre study as part of the Australian PET Data Collection Project.","volume":"112","author":"Fulham","year":"2009","journal-title":"Gynecol Oncol"},{"key":"R38-3-20210212","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ygyno.2012.04.023","article-title":". FDG PETCT in staging of advanced epithelial ovarian cancer: frequency of supradiaphragmatic lymph node metastasis challenges the traditional pattern of disease spread.","volume":"126","author":"Hynninen","year":"2012","journal-title":"Gynecol Oncol"},{"key":"R39-3-20210212","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1053\/j.semnuclmed.2015.03.005","article-title":"PETMRI evaluation of gynecologic malignancies and prostate cancer.","volume":"45","author":"Bagade","year":"2015","journal-title":"Semin Nucl Med"}],"container-title":["Nuclear Medicine Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MNM.0000000000000477","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:34:05Z","timestamp":1620963245000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006231-201605000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/mnm.0000000000000477","relation":{},"ISSN":["0143-3636"],"issn-type":[{"value":"0143-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]}}}